Novartis | NOVN - Ebitda

Stock Price
102.32
Daily Change
-1.66 -1.60%
Monthly
6.56%
Yearly
2.73%
Q3 Forecast
103.29

Novartis reported $6.17B in EBITDA for its fiscal quarter ending in June of 2025.


Ebitda Change Date
AbbVie USD 4.4B 2.52B Mar/2025
Alcon AG USD 250M 213M Jun/2025
Almirall EUR 76.3M 8.43M Mar/2025
Amgen USD 3.6B 147M Jun/2025
AstraZeneca USD 4.96B 127M Jun/2025
Autolus Therapeutics Ltd -62937000 10.93M Mar/2025
Bayer EUR 236M 3.35B Jun/2025
Biogen USD 1.01B 456.5M Jun/2025
Bristol-Myers Squibb USD 3.27B 1.63B Jun/2025
Eli Lilly USD 7.5B 3.34B Jun/2025
Fresenius EUR 828M 88M Jun/2025
Fresenius Medical Care EUR 871M 282M Jun/2025
Galapagos EUR -158708000 177.84M Mar/2025
Genmab DKK 376M 172M Jun/2025
Gilead Sciences USD 3.4B 797M Jun/2025
GlaxoSmithKline GBP 3.18B 45M Jun/2025
GRIFOLS EUR 347.24M 58.35M Jun/2025
Hikma Pharmaceutical USD 369M 84M Dec/2024
J&J USD 7.88B 1.76B Mar/2025
Lonza CHF 1.01B 139M Dec/2024
Merck EUR 1.46B 45M Jun/2025
Merck USD 7.74B 625M Mar/2025
Novartis USD 6.17B 339M Jun/2025
Novartis USD 6.08B 739M Jun/2025
Novo Nordisk 38.28B 4.34B Jun/2025
Orion EUR 118.6M 27.1M Jun/2025
Pfizer USD 5.32B 889M Jun/2025
Philips EUR 747M 174M Jun/2025
Recordati EUR 226.19M 21.6M Jun/2025
Regeneron Pharmaceuticals USD 1.66B 926.5M Jun/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Sanofi EUR 1.89B 971M Jun/2025
UCB EUR 1.37B 715M Dec/2024